FULC - Fulcrum Therapeutics Inc. (FULC) Q1 2024 Earnings Call Transcript
2024-05-13 10:38:01 ET
Fulcrum Therapeutics, Inc. (FULC)
Q1 2024 Earnings Call Transcript
May 13, 2024, 08:00 AM ET
Company Participants
Alex Sapir - CEO and President
Alan Musso - CFO
Paul Bruno - SVP of Business and Corporate Development
Iain Fraser - SVP of Early Development
Conference Call Participants
Edward Tenthoff - Piper Sandler
Gregory Renza - RBC Capital Markets
Corinne Johnson - Goldman Sachs
Joseph Schwartz - Leerink Partners
Dae Gon Ha - Stifel
Matthew Biegler - Oppenheimer
Presentation
Operator
Good morning and welcome to Fulcrum Therapeutics' First Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com and is being recorded.
Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development, timelines, and financial projections. While these forward-looking statements represent Fulcrum's views as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but it's not taking on an obligation to do so. Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business.
Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer; Dr. Iain Fraser, Senior Vice President of Early Development; and Paul Bruno, Senior Vice President of Business and Corporate Development. After providing updates on our key programs, there will be a brief Q&A in which Alex, Alan, Iain, and Paul will be available to answer your questions....
Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript